RPG Life Sciences is currently trading at Rs 82.45, up by 0.85 points or 1.04% from its previous closing of Rs 81.60 on the BSE.
The scrip opened at Rs 82.20 and has touched a high and low of Rs 82.95 and Rs 81.65 respectively. So far 376 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 8 has touched a 52 week high of Rs 122.00 on 05-Nov-2010 and a 52 week low of Rs 62.20 on 08-Dec-2010.
Last one week high and low of the scrip stood at Rs 84.00 and Rs. 76.15 respectively. The current market cap of the company is Rs 134.93 crore.
The promoters holding in the company stood at 52.02% while Institutions and Non-Institutions held 2.90% and 45.09% respectively.
Credit rating agency, CARE has revised the rating assigned to the bank facilities of RPG Life Sciences. The agency has revised the assigned ‘BBB-‘rating to ‘BBB’ to the long-term bank facilities of the company amounting Rs 25.33 crore. The agency has also revised the assigned ‘A3’ rating to ‘A3+’ to the short-term bank facilities of the company amounting Rs 40.92 crore.
Further, the agency has also revised the assigned ‘BBB-/A3’ rating to ‘BBB/A3+’ to the long-term/short-term bank facilities of the company amounting Rs 23.70 crore. However, the ratings continue to be constrained by the relatively small size of operations coupled with moderate liquidity indicators and gearing ratios. The company’s ability to achieve the projected sales and profitability together with receipt of USFDA approval remains the key rating sensitivities.
RPG Lifesciences (RPGLS), part of the RPG group, is a pharmaceutical company, engaged in manufacturing of Synthetic APIs, Biotech APIs and Formulations under its own brand name and contract manufacturing for large pharma companies. The company’s manufacturing facilities are located at Ankleshwar, Gujarat and Thane, Maharashtra.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: